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Abstract 
Background: 4-Thio-substituted phenethylamines (2C-T drugs) are potent psychedelics with 
poorly defined pharmacological properties. Because of their psychedelic effects, 2C-T drugs 
are sometimes sold as new psychoactive substances (NPSs). The aim of the present study was 
to characterize the monoamine receptor and transporter interaction profiles of a series of 2C-
T drugs. 
Methods: We determined the binding affinities of 2C-T drugs at monoamine receptors and 
transporters in human cells that were transfected with the respective receptors or transporters. 
We also investigated the functional activation of serotonergic 5-hydroxytryptamine 2A (5-
HT2A) and 5-HT2B receptors, activation of human trace amine-associated receptor 1 
(TAAR1), and inhibition of monoamine uptake transporters. 
Results: 2C-T drugs had high affinity for 5-HT2A and 5-HT2C receptors (1-54 nM and 40-350 
nM, respectively). With activation potencies of 1-53 nM and 44-370 nM, the drugs were 
potent 5-HT2A receptor and 5-HT2B receptor, respectively, partial agonists. An exception to 
this were the benzylthiophenethylamines, which did not potently activate the 5-HT2B receptor 
(EC50 > 3,000 nM). Furthermore, the compounds bound to serotonergic 5-HT1A and 
adrenergic receptors. The compounds had high affinity for the rat TAAR1 (5-68 nM) and 
interacted with the mouse but not human TAAR1. The 2C-T drugs did not potently interact 
with monoamine transporters (Ki > 4,000 nM). 
Conclusion: The receptor binding profile of 2C-T drugs predicts psychedelic effects that are 
mediated by potent 5-HT2 receptor interactions. 
 
Keywords: phenethylamines, psychedelics, receptor, affinity, new psychoactive substances 
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Abbreviations: 4-bromo-2,5-dimethoxyphenethylamine, 2C-B; 2,5-dimethoxy-4-
methylthiophenethylamine, 2C-T-1; 2,5-dimethoxy-4-(β-methallyl)thiophenethylamine, 
2C-T-3; 2,5-dimethoxy-4-isopropylthiophenethylamine, 2C-T-4; 2,5-dimethoxy-4-
propylthiophenethylamine, 2C-T-7; 2,5-dimethoxy-4-allylthiophenethylamine, 2C-T-16; 
2,5-dimethoxy-4-n-butylthiophenethylamine, 2C-T-19; 2,5-dimethoxy-4-(2,2-
difluoroethylthio)phenethylamine, 2C-T-21.5; 2,5-dimethoxy-4-(2,2,2-
trifluoroethylthio)phenethylamine, 2C-T-22; 2,5-dimethoxy-4-isobutylthiophenethylamine, 
2C-T-25; 2,5-dimethoxy-4-benzylthiophenethylamine, 2C-T-27; 2,5-dimethoxy-4-(3-
fluoropropylthio)phenethylamine, 2C-T-28; 2,5-dimethoxy-4-(4-
fluorobutylthio)phenethylamine, 2C-T-30; 2,5-dimethoxy-4-(4-
trifluoromethylbenzylthio)phenethylamine 2C-T-31; 2,5-dimethoxy-4-(3-
methoxybenzylthio)phenethylamine, 2C-T-33; 5-HT, 5-hydroxytryptamine (serotonin); 
dopamine, DA; dopamine transporter, DAT; fluorescence imaging plate reader, FLIPR; high-
performance liquid chromatography, HPLC; lysergic acid diethylamide, LSD; 
norepinephrine, NE; norepinephrine transporter, NET; new psychoactive substance, NPS; 
serotonin transporter, SERT; trace amine-associated receptor 1, TAAR1. 
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1. Introduction 
Substituted phenethylamines are a class of drugs that includes several potent 
psychedelics that exert their effects through interactions with the serotonergic 5-
hydroxytryptamine 2 (5-HT2) receptor site (Glennon et al., 1984; Glennon et al., 1982; 
Nelson et al., 1999; Nichols, 2004; Titeler et al., 1988). Many psychedelic phenethylamines 
were first synthesized by Alexander Shulgin during the 1970s and 1980s and were described 
in the book PiHKAL: A Chemical Love Story (Shulgin and Shulgin, 1995). 2C drugs are a 
subfamily of substituted phenethylamines, consisting of 2,5-dimethoxy-4-substituted 
phenethylamines. The term 2C refers to the two carbon atoms between the benzene ring and 
amino group (Shulgin and Shulgin, 1995). Originally proposed as psychotropic agents for 
psychotherapy (Shulgin and Shulgin, 1995; Shulgin and Carter, 1975), 2C drugs are now 
popular among recreational drug users because of their psychedelic and entactogenic 
properties (de Boer and Bosman, 2004; Gonzalez et al., 2015). Today, the Internet appears to 
be the main source for both acquiring information on and purchasing 2C drugs and other 
NPSs (Brandt et al., 2014; Orsolini et al., 2017; Schifano, 2005). Although classic 2C drugs 
are considered physiologically safe, several incidences, including sympathomimetic toxicity, 
psychosis, and death, have been documented (Bosak et al., 2013; Curtis et al., 2003; Huang 
and Bai, 2011; Miyajima et al., 2008; Stoller et al., 2017). Additionally, several 2C fatalities 
have been reported in the media (Dean et al., 2013). Moreover, newly emerged highly potent 
phenethylamine hallucinogens, including N-(2-methoxybenzyl)-2,5-dimethoxy-4-substituted 
(“NBOMe”) phenethylamines, were found to be unexpectedly toxic and recently associated 
with several fatalities (Nichols, 2016; Nikolaou et al., 2015; Poklis et al., 2014; Rose et al., 
2013; Suzuki et al., 2015). We previously reported the receptor and transporter interaction 
profiles of 2C drugs compared with their NBOMe analogs (Rickli et al., 2015). The sulfur-
containing 2C drugs (2C-T-2, 2C-T-4, and 2C-T-7) that were included in the study proved to 
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be potent agonists at 5-HT2 receptors (Rickli et al., 2015). Several other compounds of the 
2C-T series have been described (Shulgin and Shulgin, 1995; Trachsel, 2003), but little 
information is available regarding their interactions with monoamine receptors and 
transporters. On Internet drug discussion websites such as bluelight.org, the most commonly 
discussed 2C-T drugs are 2C-T-2, 2C-T-4, 2C-T-7, and 2C-T-21. Other compounds of the 
series are only sporadically mentioned and their use does currently not seem to be 
widespread. However, NPSs constantly emerge and it is possible that several other 2C-T 
compounds will appear on the drug market in the future. 
 In the present study, we determined and compared the monoamine receptor and 
transporter affinities of 14 compounds of the 2C-T series (Fig. 1). The numbering of the 
compounds of the 2C-T series describes the sequence of construction and has no structural 
relationship (Shulgin and Shulgin, 1995). 2C-T-3 was first named 2C-T-20; however, 
because its amphetamine analog 2,5-dimethoxy-4-(beta-methallylthio)amphetamine was 
originally named Aleph-3, 2C-T-20 was later renamed 2C-T-3 to maintain consistency 
between the 2C-T and Aleph series (Shulgin and Shulgin, 1995). The unusual number of 2C-
T-21.5 is based on the fact that with its difluoroethylthio substitution, 2C-T-21.5 lies between 
the mono-fluorinated 2C-T-21 and tri-fluorinated 2C-T-22 (Shulgin and Shulgin, 1995). 
 
2. Material and Methods 
2.1. Drugs 
The 2C-T drugs were synthesized as hydrochlorides as described previously (Shulgin 
and Shulgin, 1995; Trachsel, 2003) and provided by ReseaChem GmbH. High-performance 
liquid chromatography (HPLC) purity was > 98.5%. 4-Bromo-2,5-dimethoxyphenethylamine 
(2C-B) hydrochloride, d-methamphetamine hydrochloride, and lysergic acid diethylamide 
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(LSD) were purchased from Lipomed (Arlesheim, Switzerland), with high-performance 
liquid chromatography (HPLC) purity > 98.5%. 
 
2.2. 5-HT1A and 5-HT2A receptor radioligand binding assays 
For membrane preparations, HEK 293 cells that were transiently transfected with the 
5-HT1A or 5-HT2A receptor were released from the culture flasks using 
trypsin/ethylenediaminetetraacetic acid (EDTA), harvested, washed twice with ice-cold 
phosphate-buffered saline (PBS; without Ca2+ and Mg2+), pelleted at 1,000 rotations per 
minute (rpm) for 5 min at 4°C, frozen, and stored at -80°C. Frozen pellets were suspended in 
20 ml HEPES-NaOH (20 mM, pH 7.4) that contained 10 mM EDTA and homogenized with 
a Polytron (PT 6000, Kinematica, Luzern, Switzerland) at 14,000 rpm for 20 s. The 
homogenates were centrifuged at 48,000 × g for 30 min at 4°C. Subsequently, the 
supernatants were removed and discarded, and the pellets were resuspended in 20 ml 
HEPES-NaOH (20 mM, pH 7.4) that contained 0.1 mM EDTA using the Polytron (20 s at 
14,000 rpm). This procedure was repeated, and the final pellets were resuspended in HEPES-
NaOH that contained 0.1 mM EDTA and homogenized using the Polytron. Typically, 
aliquots of 2 ml membrane portions were stored at -80°C. With each new membrane batch, 
the dissociation constant (Kd) was determined by a saturation curve. 
For the competitive binding assays, [3H]-8-OH-DPAT and [3H]-ketanserin were used 
as 5-HT1A and 5-HT2A receptor radioligands, respectively, at concentrations equal or close to 
the Kd values. Specific binding of the radioligands to the target receptors was defined as the 
difference between total binding (binding buffer alone) and nonspecific binding that was 
determined in the presence of 10 µM pindolol (for the 5-HT1A receptor radioligand) or 10 µM 
spiperone (for the 5-HT2A receptor radioligand). The compounds were tested at a broad range 
of concentrations (30 pM to 30 µM) in duplicate. The test compounds were diluted in binding 
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assay buffer at pH 7.4 (50 mM Tris/HCl, 10 mM MgCl2, and 1 mM EGTA), and dilution 
curves were constructed in assay microplates (Greiner, 96-well, U-bottom, PS). Radioligand 
(50 µl) and the membrane suspension (100 µl) were added to the assay plates to a final 
volume of 200 µl in each well and incubated and shaken for 30 min at room temperature. 
Incubations were terminated by rapid filtration through Unifilter-96 plates (Packard 
Instrument Company, PerkinElmer, Schwerzenbach, Switzerland) and GF/C glass filters 
(PerkinElmer) that were presoaked for a minimum of 1 h in 0.3% polyethylenimine and 
washed three times with ice-cold washing buffer (50 mM Tris/HCl, pH 7.4). After the 
addition of Microscint 40 (45 µl/well, PerkinElmer), the Unifilter-96 plates were sealed. 
After 1 h, radioactivity was counted using a TopCount Microplate Scintillation Counter 
(Packard Instrument Company). IC50 values were determined by calculating nonlinear 
regression curves for a one-site model using at least three independent 10-point 
concentration-response curves, run in duplicate, for each compound. Ki (affinity) values, 
which correspond to the dissociation constants, were determined using the Cheng-Prusoff 
equation: Ki = IC50 / (1 + radioligand concentration / Kd). Ki values are presented as means ± 
SD (in µM). 
 
2.3. 5-HT2C receptor radioligand binding assay 
For membrane preparations, HEK 293 cells that were transiently transfected with the 
5-HT2C receptor were released from the culture flasks using trypsin/EDTA, harvested, 
washed twice with ice-cold PBS (without Ca2+ and Mg2+), pelleted at 1,000 rpm for 5 min at 
4°C, frozen, and stored at -80°C. Frozen pellets were suspended in 20 ml HEPES/NaOH (20 
mM, pH 7.4) that contained 10 mM EDTA and homogenized with a Polytron (PT 6000, 
Kinematica) at 14,000 rpm for 20 s. The homogenates were centrifuged at 48,000 × g for 30 
min at 4°C. Subsequently, the supernatants were removed and discarded, and the pellets were 
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resuspended in 20 ml HEPES-NaOH (20 mM, pH 7.4) that contained 0.1 mM EDTA using 
the Polytron (20 s at 14,000 rpm). This procedure was repeated, and the final pellets were 
resuspended in HEPES/NaOH that contained 0.1 mM EDTA and homogenized using the 
Polytron. Typically, 2 ml aliquots of membrane portions were stored at -80°C. With each 
new membrane batch, the dissociation constant (Kd) was determined by a saturation curve. 
For the competitive binding assay, [3H]-mesulergine was used as the 5-HT2C receptor 
radioligand at a concentration equal or close to the Kd value. Specific binding of the 
radioligand to the target receptor was defined as the difference between total binding (binding 
buffer alone) and nonspecific binding that was determined in the presence of 10 µM 
mianserin. The compounds were tested at a broad range of concentrations (30 pM to 30 µM) 
in duplicate. The test compounds were diluted in binding assay buffer at pH 7.4 (50 mM 
Tris/HCl, 10 mM MgCl2, 1 mM EGTA, and 10 µM pargyline), and dilution curves were 
constructed in 96-well white polystyrene assay plates (Sigma-Aldrich, Buchs, Switzerland). 
Membrane stocks were thawed and resuspended to a concentration of approximately 0.04 mg 
protein/ml binding assay buffer using a Polytron tissue homogenizer. The membrane 
homogenate (40 µg/ml) was then lightly mixed for 5-30 min with YSi-poly-L-lysine 
(PerkinElmer) at 0.5 mg beads/well. The membrane/bead mixture (50 µl) was added to each 
well of the assay plate that contained the radioligand (50 µl) and the test compounds (final 
volume in each well, 200 µl) to start the assay. The assay plates were sealed, incubated for 2 
h at room temperature with agitation, and then counted in the PVT SPA counting mode of a 
TopCount Microplate Scintillation Counter (Packard Instrument Company). IC50 values were 
determined by calculating nonlinear regression curves for a one-site model using at least 
three independent 10-point concentration-response curves, run in duplicate, for each 
compound. Ki (affinity) values, which correspond to the dissociation constants, were 
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determined using the Cheng-Prusoff equation: Ki = IC50 / (1 + radioligand concentration / 
Kd). Ki values are presented as means ± SD (in µM). 
 
2.4. Rat and mouse TAAR1 receptor radioligand binding assays 
HEK 293 cells that stably expressed rat or mouse TAAR1 were used as described 
previously (Revel et al., 2011). All of the cell lines were maintained at 37°C and 5% CO2 in 
high-glucose Dulbecco’s modified Eagle’s medium (DMEM) that contained 10% fetal calf 
serum (heat-inactivated for 30 min at 56°C), 1% penicillin/streptomycin, and 375 µg/ml 
Geneticin (Gibco, Zug, Switzerland). For membrane preparation, the cells were released from 
the culture flasks using trypsin/EDTA, harvested, washed twice with ice-cold PBS (without 
Ca2+ and Mg2+), pelleted at 1000 × g for 5 min at 4°C, frozen, and stored at -80°C. Frozen 
pellets were suspended in buffer A (20 ml HEPES-NaOH [20 mM, pH 7.4] that contained 10 
mM EDTA) and homogenized with a Polytron (PT 6000; Kinematica) at 14,000 rpm for 20 s. 
The homogenate was centrifuged for 30 min at 48,000 × g at 4°C. The supernatant was 
removed and discarded, and the pellet was resuspended in buffer A using the Polytron (20 s 
at 14,000 rpm). The centrifugation and removal of the supernatant was repeated, and the final 
pellet was resuspended in buffer A and homogenized using the Polytron. Typically, 2-ml 
aliquots of membrane portions were stored at -80°C. With each new membrane batch, the 
dissociation constant (Kd) was determined by a saturation curve. 
For the competitive binding assays, the TAAR1 agonist [3H]-RO5166017 was used as 
a TAAR1 radioligand at a concentration equal or close to the Kd values, which were usually 
around 0.7 nM (mouse TAAR1) and 2.3 nM (rat TAAR1). Nonspecific binding was defined 
as the amount of radioligand that bound in the presence of 10 µM RO5166017. Compounds 
were tested at a broad range of concentrations (30 pM to 30 µM) in duplicate. Compounds 
(20 µl/well) were transferred to a 96-deep-well plate (TreffLab, Degersheim, Switzerland), 
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and 180 µl of binding buffer (20 mM HEPES-NaOH, 10 mM MgCl2, and 2 mM CaCl2, pH 
7.4), 300 µl of radioligand, and 500 µl of membranes (resuspended at 60 µg protein/ml) were 
added. The plates were incubated at 4°C for 90 min. Incubations were terminated by rapid 
filtration through Unifilter-96 plates (Packard Instrument Company) and GF/C glass filters 
(PerkinElmer) that were presoaked for 1 h in 0.3% polyethylenimine and washed three times 
with 1 ml of cold binding buffer. After the addition of Microscint 40 (45 µl/well, 
PerkinElmer), the Unifilter-96 plate was sealed. After 1 h, radioactivity was counted using a 
TopCount Microplate Scintillation Counter (Packard Instrument Company). IC50 values were 
determined by calculating nonlinear regression curves for a one-site model using at least 
three independent 10-point concentration-response curves, run in duplicate, for each 
compound. Ki (affinity) values, which correspond to the dissociation constants, were 
determined using the Cheng-Prusoff equation. Ki values are presented as means ± SD (in 
µM). 
 
2.5. Adrenergic α1A and α2A receptor radioligand binding assays 
CHO cells were stably transfected with the adrenergic α1A receptor and maintained at 
37°C and 5% CO2 in HAM’s F12 medium (Invitrogen) that contained 10% fetal calf serum 
(heat inactivated for 30 min at 56°C), 150 μg/ml Geneticin (Gibco, Zug, Switzerland), and 
1% penicillin/streptomycin. CHL cells that stably expressed the adrenergic α2A receptor were 
maintained at 37°C and 5% CO2 in high-glucose DMEM that contained 5% fetal calf serum 
(heat inactivated for 30 min at 56°C) and 250 μg/ml Geneticin (Gibco, Zug, Switzerland).   
For membrane preparations, the cells were released from the culture flasks using 
trypsin/EDTA, harvested, washed twice with ice-cold PBS (without Ca2+ and Mg2+), pelleted 
at 1,000 rpm for 5 min at 4°C, frozen, and stored at -80°C. Frozen pellets were suspended in 
20 ml HEPES-NaOH (20 mM, pH 7.4) that contained 10 mM EDTA and homogenized with 
	   11	  
a Polytron (PT 6000, Kinematica) at 14,000 rpm for 20 s. The homogenates were centrifuged 
at 48,000 × g for 30 min at 4°C. Subsequently, the supernatants were removed and discarded, 
and the pellets were resuspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) that contained 
0.1 mM EDTA using the Polytron (20 s at 14,000 rpm). This procedure was repeated, and the 
final pellets were resuspended in HEPES-NaOH that contained 0.1 mM EDTA and 
homogenized using the Polytron. Typically, 2 ml aliquots of membrane portions were stored 
at -80°C. With each new membrane batch, the dissociation constant (Kd) was determined by a 
saturation curve. 
For the competitive binding assays, [3H]-prazosin and [3H]-rauwolscine were used as 
adrenergic α1A and adrenergic α2A receptor radioligands, respectively, at concentrations equal 
or close to the Kd values. Specific binding of the radioligands to the target receptors was 
defined as the difference between total binding (binding buffer alone) and nonspecific 
binding that was determined in the presence of 10 µM chlorpromazine (for the α1A receptor 
radioligand) and 10 µM phentolamine (for the α2A receptor radioligand). The compounds 
were tested at a broad range of concentrations (30 pM to 30 µM) in duplicate. The test 
compounds were diluted in binding assay buffer (50 mM Tris/HCl, pH 7.4), and dilution 
curves were constructed in assay microplates (Greiner, 96 well, U-bottom, PS). Radioligand 
50 µl) and the membrane suspension (100 µl) were added to the assay plates and incubated 
and shaken for 1 h at room temperature. Incubations were terminated by rapid filtration 
through Unifilter-96 plates (Packard Instrument Company) and GF/C glass filters 
(PerkinElmer) that were presoaked for 1 h in 0.3% polyethylenimine and washed three times 
with 1 ml cold binding assay buffer. After the addition of Microscint 40 (45 µl/well, 
PerkinElmer), the Unifilter-96 plates were sealed. After 1 h, radioactivity was counted using 
a TopCount Microplate Scintillation Counter (Packard Instrument Company). IC50 values 
were determined by calculating nonlinear regression curves for a one-site model using at least 
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three independent 10-point concentration-response curves, run in duplicate, for each 
compound. Ki (affinity) values, which correspond to the dissociation constants, were 
determined using the Cheng-Prusoff equation: Ki = IC50 / (1 + radioligand concentration / 
Kd). Ki values are presented as means ± SD (in µM).  
 
2.6. D2 receptor radioligand binding assay 
For membrane preparations, HEK 293 cells that were transiently transfected with the 
dopamine D2 receptor were released from the culture flasks using trypsin/EDTA, harvested, 
washed twice with ice-cold PBS (without Ca2+ and Mg2+), pelleted at 1,000 rpm for 5 min at 
4°C, frozen, and stored at -80°C. Frozen pellets were suspended in 20 ml of HEPES-NaOH 
(20 mM, pH 7.4) that contained 10 mM EDTA and homogenized with a Polytron (PT 6000, 
Kinematica) at 14,000 rpm for 20 s. The homogenates were centrifuged at 48,000 × g for 30 
min at 4°C. Subsequently, the supernatants were removed and discarded, and the pellets were 
resuspended in 20 ml of HEPES-NaOH (20 mM, pH 7.4) that contained 0.1 mM EDTA using 
the Polytron (20 s at 14,000 rpm). This procedure was repeated, and the final pellets were 
resuspended in HEPES-NaOH that contained 0.1 mM EDTA and homogenized using the 
Polytron. Typically, 2 ml aliquots of membrane portions were stored at -80°C. With each 
new membrane batch, the dissociation constant (Kd) was determined by a saturation curve. 
For the competitive binding assays, [3H]-spiperone was used as the dopamine D2 
receptor radioligand at a concentration equal or close to the Kd value. Specific binding of the 
radioligand to the target receptor was defined as the difference between total binding (binding 
buffer alone) and nonspecific binding that was determined in the presence of 10 µM 
spiperone. The compounds were tested at a broad range of concentrations (30 pM to 30 µM) 
in duplicate. The test compounds were diluted in binding assay buffer at pH 7.4 (50 mM 
Tris/HCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, and 120 mM NaCl), and 
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dilution curves were constructed in assay microplates (Greiner, 96 well, U-bottom, PS). 
Radioligand (50 µl) and the membrane suspension (100 µl) were added to the assay plates 
(final volume in each well, 200 µl) and incubated and shaken for 1 h at room temperature. 
Incubations were terminated by rapid filtration through Unifilter-96 plates (Packard 
Instrument Company) and GF/C glass filters (PerkinElmer) that were presoaked for a 
minimum of 1 h in 0.3% polyethylenimine and washed three times with ice-cold washing 
buffer (50 mM Tris/HCl, pH 7.4). After the addition of Microscint 40 (45 µl/well, 
PerkinElmer), the Unifilter-96 plates were sealed. After 1 h, radioactivity was counted using 
a TopCount Microplate Scintillation Counter (Packard Instrument Company). IC50 values 
were determined by calculating nonlinear regression curves for a one-site model using at least 
three independent 10-point concentration-response curves, run in duplicate, for each 
compound. Ki (affinity) values, which correspond to the dissociation constants, were 
determined using the Cheng-Prusoff equation: Ki = IC50 / (1 + radioligand concentration / 
Kd). Ki values are presented as means ± SD (in µM).  
 
2.7. Monoamine transporter radioligand binding assays 
HEK 293 cells that stably expressed the human norepinephrine transporter (hNET), 
human serotonin transporter (hSERT), or human dopamine transporter (hDAT) were 
cultured, and cells were collected and washed three times with ice-cold PBS, pelleted at 
1,000 rpm for 5 min at 4°C, frozen, and stored at -80°C. Frozen pellets were then 
resuspended in 400 ml of HEPES-NaOH (20 mM, pH 7.4) that contained EDTA (10 mM) at 
4°C. After homogenization with a Polytron (PT 6000, Kinematics) at 10,000 rpm for 15 s, the 
homogenates were centrifuged at 48,000 × g for 30 min at 4°C. Aliquots of the membrane 
stocks were frozen at -80°C. 
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For the competitive binding assays, N-methyl-[3H]-nisoxetine, [3H]-citalopram, and 
[3H]-WIN35,428 were used as hNET, hSERT, and hDAT radioligands, respectively, at 
concentrations equal or close to the Kd values. Specific binding of the radioligand to the 
target transporters was defined as the difference between total binding (binding buffer alone) 
and nonspecific binding that was determined in the presence of 10 µM indatraline. The 
compounds were tested at a broad range of concentrations (30 pM to 30 µM) in duplicate. 
The test compounds were diluted in binding assay buffer at pH 7.4 (126 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 1.76 mM KH2PO4), and dilution curves were constructed in 96-
well OptiPlates (PerkinElmer). Membrane stocks were thawed and resuspended to a 
concentration of approximately 60 µg protein/ml binding assay buffer using a Polytron tissue 
homogenizer. The membrane homogenates were then lightly mixed for 5-30 min with 
polyvinyl toluene (PCT) wheatgerm agglutinin-coated scintillation proximity assay beads 
(WGA-SPA, Amersham Biosciences) at 11.5 mg beads/well. The membrane/bead mixture 
(50 µl) was added to each well of the assay plate that contained the radioligand (50 µl) and 
the test compounds (final volume in each well, 200 µl) to start the assay. The assay plates 
were sealed, incubated for 2 h at room temperature with agitation, and counted in the PVT 
SPA counting mode of a TopCount Microplate Scintillation Counter (Packard Instrument 
Company). IC50 values were determined by calculating nonlinear regression curves for a one-
site model using at least three independent 10-point concentration-response curves, run in 
duplicate, for each compound. Ki (affinity) values, which correspond to the dissociation 
constants, were determined using the Cheng-Prusoff equation: Ki = IC50 / (1 + radioligand 
concentration / Kd). Ki values are presented as means ± SD (in µM). 
 
2.8. Functional activity at the serotonin 5-HT2A receptor 
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Mouse embryonic fibroblasts (NIH-3T3 cells) that expressed the human 5-HT2A 
receptor were incubated in HEPES-Hank’s Balanced Salt Solution (HBSS) buffer (Gibco, 
Zug, Switzerland; 70,000 cells/100 µl) for 1 h at 37°C in 96-well poly-D-lysine-coated plates. 
To each well, 100 µl of dye solution (fluorescence imaging plate reader [FLIPR] calcium 5 
assay kit; Molecular Devices, Sunnyvale, CA, USA) was added, and the plates were 
incubated for 1 h at 37°C. The plates were placed in a FLIPR, and 25 µl of the test drugs that 
were diluted in HEPES-HBSS buffer that contained 250 mM probenicid was added online. 
The increase in fluorescence was then measured, and EC50 values were derived from the 
concentration-response curves using nonlinear regression. The maximal receptor activity 
(efficacy) is expressed relative to 5-HT activity, which was set to 100%. 
 
2.9. Functional activity at the serotonin 5-HT2B receptor  
HEK 293 cells that expressed the human 5-HT2B receptor were incubated in growth 
medium (high-glucose DMEM; Invitrogen, Zug, Switzerland), 10 ml/L 
penicillin/streptomycin (Gibco, Zug, Switzerland), 10% fetal calf serum (non-dialyzed, heat-
inactivated), and 250 mg/L Geneticin at a density of 50,000 cells/well at 37°C in poly-D-
lysine-coated 96-well plates overnight. The growth medium was then removed by snap 
inversion, and 100 µl of the calcium indicator Fluo-4 solution (Molecular Probes, Eugene, 
OR, USA) was added to each well. The plates were incubated for 45 min at 31°C before the 
Fluo-4 solution was removed by snap inversion, and 100 µl of Fluo-4 solution was added a 
second time for 45 min at 31°C. The cells were washed with HBSS and 20 mM HEPES 
(assay buffer) immediately before testing using an EMBLA cell washer, and 100 µl assay 
buffer was added. The plates were placed in a FLIPR, and 25 µl of the test substances that 
were diluted in assay buffer was added online. The increase in fluorescence was then 
measured, and EC50 values were derived from the concentration-response curves using 
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nonlinear regression. The maximal receptor activity (efficacy) is expressed relative to 5-HT 
activity, which was set to 100%. 
 
2.10. Functional activity at the human TAAR1 receptor 
 Recombinant HEK 293 cells that expressed human TAAR1 were grown at 37°C and 
5% CO2/95% air in 250 ml Falcon culture flasks in 30 ml of culture medium. The cell culture 
medium contained high-glucose DMEM, 10% fetal calf serum (heat inactivated for 30 min at 
56°C), 500 µg/ml Geneticin (Gibco), and 500 µg/ml hygromycin B. Cells were harvested 
when 80-90% confluence was reached. The culture medium was removed from the culture 
flasks, and the cells were washed once with 5 ml of PBS. After removing the wash solution, 5 
ml of trypsin/EDTA solution was added for 5 min at 37°C. Afterward, 45 ml of culture 
medium was added to the 5 ml detached cell solution, and 50 ml was transferred to a Falcon 
tube. The tube was centrifuged at 900 rpm for 3 min at room temperature, and the supernatant 
was removed. The cell pellet was resuspended in fresh culture medium and brought to 5 × 105 
cells per ml. The cells were then plated into 96-well plates (BIOCOAT 6640, Becton 
Dickinson, Allschwil, Switzerland) with a multipipette (100 µl/well, 80,000 cells/well) and 
incubated for 20 h at 37°C. For the cAMP assay, the cell culture medium was removed, and 
50 µl of PBS (without Ca2+ and Mg2+) was added. Afterward, PBS was removed by snap 
inversion followed by gently tapping of the plate on a tissue. Krebs-Ringer bicarbonate buffer 
(90 µl; Sigma-Aldrich) that contained 1 mM IBMX was added, and the plates were incubated 
for 60 min at 37°C and 5% CO2/95% air. All of the compounds were tested at a broad range 
of concentrations (300 pM to 30 µM) in duplicate, and a standard curve (0.13 nM to 10 µM 
cAMP) was constructed on each plate. A reference plate that included RO5256390, β-
phenylethylamine, and p-tyramine also accompanied each experiment. Typically, 30 µl of a 
compound solution, 30 µl of β-phenylethylamine (as maximal response), or a basal control in 
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PBS that contained 1 mM IBMX was then added, and the cells were incubated for 40 min at 
37°C. Afterward, the cells were lysed with 50 µl of 3x detection mix solution that contained 
Ru-cAMP Alexa700 anti-cAMP antibody and lysis buffer for 120 min at room temperature 
under strong shaking using black lids. Fluorescence was measured using a NanoScan (IOM 
reader; 456 nm excitation wavelength; 630 and 700 nm emission wavelengths). The FRET 
signal was calculated as the following: FRET (700 nM) – P × FRET (630 nM), where P = Ru 
(700 nM) / Ru (630 nM). 
 
2.11. Monoamine uptake transporter inhibition 
The monoamine transporter inhibition potential of the 2C-T drugs was assessed for a 
single high concentration of 10 µM to exclude activity. Monoamine uptake was determined in 
HEK 293 cells that stably expressed the hNET, hDAT, and hSERT (Tatsumi et al., 1997) as 
previously described in detail (Hysek et al., 2012). Briefly, cells were cultured to 70-90% 
confluence in DMEM (10% fetal calf serum and 250 µg/ml Geneticin, both from Gibco), 
detached, and resuspended in Krebs-Ringer bicarbonate buffer (Sigma-Aldrich) at a density 
of 3 × 106 cells/ml. For [3H]-DA uptake experiments, the uptake buffer was supplemented 
with 0.2 mg/ml ascorbic acid. The cell suspension (100 µl) was incubated with 25 µl of the 
test drugs, vehicle control, and transporter-specific inhibitors (10 µM nisoxetine for NET, 10 
µM mazindol for DAT, and 10 µM fluoxetine for SERT) dissolved in buffer for 10 min in a 
round-bottom 96-well plate at room temperature at 450 rpm on a rotary shaker. Monoamine 
uptake transport was then initiated by adding 50 µl of [3H]-NE (13.1 Ci/mmol; PerkinElmer), 
[3H]-DA (30.0 Ci/mmol, PerkinElmer), or [3H]-5-HT (80.0 Ci/mmol; Anawa, Zürich, 
Switzerland) dissolved in buffer at a final concentration of 5 nM for an additional 10 min. 
The cell suspension (100 µl) was then transferred to 500 µl microcentrifuge tubes that 
contained 50 µl of 3 M KOH and 200 µl silicon oil (1:1 mixture of silicon oil types AR 20 
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and AR 200; Sigma-Aldrich). To separate the cells from the uptake buffer, they were 
centrifuged through silicone oil for 3 min at 16,550 × g, and the tubes were frozen in liquid 
nitrogen immediately afterward. The cell pellet was then cut into 6 ml scintillation vials 
(PerkinElmer) that contained 0.5 ml lysis buffer (0.05 M Tris-HCl, 50 mM NaCl, 5 mM 
EDTA, and 1% NP-40 in water), and the samples were shaken for 1 h before 5 ml of 
scintillation fluid (Ultimagold, PerkinElmer) was added. Monoamine uptake was then 
quantified by liquid scintillation counting on a Packard 1900 TR Tri-Carb Liquid 
Scintillation Counter (Packard Instrument Company). Nonspecific uptake that was 
determined in the presence of selective inhibitors was subtracted from the total counts, and 
monoamine uptake was compared with the vehicle control. 
 
2.12. Statistical analysis 
IC50 values of radioligand binding were determined by calculating nonlinear 
regression curves for a one-site model using at least three independent 10-point 
concentration-response curves for each substance. Ki (affinity) values, which correspond to 
the dissociation constants, were calculated using the Cheng-Prusoff equation. Nonlinear 
regression concentration-response curves were used to determine EC50 values for 5-HT2A and 
5-HT2B receptor activation. Efficacy (maximal activity) is expressed relative to the activity of 
5-HT, which was used as a control set to 100%. Monoamine uptake of three independent 
experiments was compared with vehicle controls using analysis of variance followed by 
Dunnett’s multiple-comparison test. 
 
3. Results 
3.1. Interactions with serotonin receptors 
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The binding affinities and activation potency of 2C-T drugs to serotonin receptors are 
listed in Table 1. All of the drugs bound to the 5-HT1A receptor in the range of 660-2,370 nM 
and bound to the 5-HT2A receptor in the range of 1-54 nM, with an activation potency of 1-53 
nM and activation efficacy of 3-75%. All of the drugs except 2C-T-27 and 2C-T-33 activated 
the 5-HT2B receptor, with an activation potency of 44-3,310 nM and activation efficacy of 
28-75%. All of the drugs bound to the 5-HT2C receptor with affinities of 40-350 nM. 2C-B 
and LSD were included in Table 1 as reference psychedelics for comparison.  
 
3.2. Binding to monoamine receptors and transporters 
Binding affinities of 2C-T drugs to monoamine transporters and receptors are listed in 
Table 2. None of the drugs bound to the tested binding region of the NET at the investigated 
concentration range. Only 2C-T-27, 2C-T-31, and 2C-T-33 bound to the DAT, with affinities 
of 4.8-7.7 µM. Only 2C-T-3 bound to the SERT, with a Ki of 7.2 µM. No affinity for 
adrenergic α1A or dopamine D2 receptors was detected in vitro, with the exception of 2C-T-
28, 2C-T-30, 2C-T-31, and 2C-T-33, which bound to the α1A receptor with a Ki of 2.3-3.6 
µM. However, the drugs bound to the α2A receptor in the range of 97-804 nM. Furthermore, 
the drugs bound to rat and mouse TAAR1, with affinities of 5-68 nM and 55-2,340 nM, 
respectively, but did not activate the human TAAR1 at the investigated concentration range. 
As reference, the TAAR1 interactions of the partial agonist (Simmler et al., 2016) d-
methamphetamine are listed in Table 2. 
 
3.3. Monoamine uptake transporter inhibition 
 No significant NE, DA, or 5-HT uptake inhibition was observed for any of the 2C-T 
drugs at 10 µM (data not shown). 
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4. Discussion 
The compounds had 17- to 830-fold higher affinity for the 5-HT2A vs. 5-HT1A 
receptor and 4- to 44-fold higher affinity for the 5-HT2A vs. 5-HT2C receptor. Similarly, 
selectivity for the 5-HT2 receptor site has been shown for 2C drugs, NBOMe derivatives, and 
phenylisopropylamine hallucinogens (substituted amphetamines) but not for other 
psychedelics of the tryptamine class or LSD (Fantegrossi et al., 2005; Halberstadt and Geyer, 
2011; Pierce and Peroutka, 1989; Rickli et al., 2015; Rickli et al., 2016; Titeler et al., 1988). 
In accordance with those findings, in our study 2C-B had selectivity ratios in the range of the 
2C-T drugs and LSD was less selective with 5-HT2A vs. 5-HT1A and 5-HT2A vs. 5-HT2C ratios 
of 0.28 and 2.6, respectively. 
The three benzylthiophenethylamines (2C-T-27, 2C-T-31, and 2C-T-33) most 
potently bound to the 5-HT2A receptor, with affinities of 1.6-3.8 nM. However, they had the 
lowest receptor activation potential for the 5-HT2A receptor (26-53 nM) and negligible or no 
activation potential for the 5-HT2B receptor. These three benzylthiophenethylamines also 
most potently bound to the 5-HT2A receptor in a previous test series of 11 2C-T drugs using 
[3H]-LSD as the radioligand (Trachsel et al., 2013). High affinity and antagonistic properties 
could be expected because of the bulky and lipophilic 4-substituent (Hansen et al., 2014; 
Nichols et al., 1977; Seggel et al., 1990). The remaining compounds all activated the 5-HT2A 
and 5-HT2B receptors in the range of 1-15 nM and 44-370 nM, respectively, with an 
activation efficacy of 36-75% and 28-75%, respectively. Drugs of the 2C-T series can 
therefore be classified as partial agonists as previously shown for other 2C drugs (Moya et 
al., 2007; Rickli et al., 2015) and similar psychedelic effects may be expected. Several 
fluorine-containing compounds were investigated. The 5-HT2A and 5-HT2C receptor affinity 
of 2C-T-7 was higher (3.2- and 2.5-fold, respectively) compared with its monofluorinated 
analog 2C-T-28. Compared with its monofluorinated analog 2C-T-30, 5-HT2 binding affinity 
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also increased for 2C-T-19 (1.4- and 1.6-fold increase in affinity for 5-HT2A and 5-HT2C 
receptors, respectively). A decrease in affinity by fluorine has previously been described for 
2C-T-30 in radioligand binding assays using [3H]-LSD-labeled cloned 5-HT2A receptors 
(Trachsel, 2012). However, although 2C-T-7 had a higher activation potential for 5-HT2A and 
5-HT2B receptors compared with 2C-T-28, the activation potential of 2C-T-19 for both 
receptors was lower compared with 2C-T-30. The difluoroethyl derivative 2C-T-21.5 and 
trifluoroethyl derivative 2C-T-22 had comparable affinities for 5-HT2A and 5-HT2C receptors. 
However, 2C-T-21.5 had a higher activation potential for the 5-HT2A receptor, whereas 2C-
T-22 had a higher activation potential for the 5-HT2B receptor. In a previous study (Rickli et 
al., 2015), 2C-T-2, the non-fluorinated analog of 2C-T-21.5 and 2C-T-22, had slightly higher 
affinity for 5-HT2A and 5-HT2C receptors (9 and 67 µM, respectively) compared with 2C-T-
21.5 and 2C-T-22. In the present study, however, the 5-HT2A and 5-HT2B receptor activation 
potency of 2C-T-21.5 and 2C-T-22, respectively, was higher than the previously determined 
receptor activation potency for 2C-T-2 (Rickli et al., 2015). Therefore, although terminal 
fluorinating appears to decrease 5-HT receptor affinity, it may increase activation potential in 
some cases. 
In the radioligand binding assay, none of the substances bound to the investigated 
NET binding site, and none of the compounds significantly inhibited NE uptake at 10 µM. 
Only 2C-T-27, 2C-T-31, and 2C-T-33 bound to the DAT, with affinities of 4.8-7.7 µM. Only 
2C-T-3 bound to the SERT, with an affinity of 7.2 µM. However, no DA or 5-HT uptake 
inhibition was observed for any of the compounds at 10 µM. Transporter binding and 
inhibition may occur at higher concentrations, which has been shown previously for 2C-T-2, 
2C-T-4, and 2C-T-7 (Rickli et al., 2015). However, given the potent interactions with 
serotonergic receptors, the monoamine transporter interactions of 2C-T drugs are likely not 
clinically relevant and were not investigated at higher concentrations in the present study. No 
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interactions with dopaminergic D2 or adrenergic α1A receptors were observed in the 
radioligand binding assays, with the exception of low-affinity binding of 2C-T-28, 2C-T-30, 
2C-T-31, and 2C-T-33 to the α1A receptor. However, all of the drugs bound to the α2A 
receptor, with an affinity of 97-804 nM. The selectivity for α2A over α1A receptors has 
previously been reported for 2C drugs but not NBOMe compounds, which bound to both 
receptors with submicromolar affinity (Rickli et al., 2015). All of the drugs potently bound to 
the rat TAAR1 in the range of 5-68 nM and less potently to the mouse TAAR1 in the range of 
55-2,340 nM. However, the compounds were inactive at the human TAAR1 in the functional 
assays (EC50 > 30 µM). Consistent with our results, a rank order affinity for rat > mouse > 
human TAAR1 has previously been described for substituted phenethylamines with bulky 
residues (Lewin et al., 2008; Simmler et al., 2016; Wainscott et al., 2007). 
The psychoactive dose of phenethylamines cannot be explained solely by data from in 
vitro assays. For example, Shulgin proposed a dose of 60-100 mg and duration of 3-5 h for 
2C-T-1; for 2C-T-4, he proposed a human dose of 8-20 mg and duration of 12-18 h (Shulgin 
and Shulgin, 1995). However, receptor binding affinities in the radioligand assays for these 
two compounds were comparable, and the activation potential for the 5-HT2A receptor was 
even higher for 2C-T-1 than for 2C-T-4. Therefore, other factors, such as lipophilicity, 
functional selectivity, and monoamine oxidase (MAO) and cytochrome P450 (CYP) 
metabolism, may influence the dose and effect of the compounds. Shulgin mentioned an 
unusual subjective variability for 2C-T drugs in the book PiHKAL (Shulgin and Shulgin, 
1995). MAO-A, MAO-B, and to a lesser extent CYP2D6 were identified as the main 
enzymes that are involved in the deamination of 2C-T-2 and 2C-T-7 (Theobald and Maurer, 
2007). A study with methoxylated and alkylthio amphetamine derivatives, however, did not 
find a correlation between the MAO inhibitory potential of the drugs and hallucinogenic 
potency reported in humans (Scorza et al., 1997). Other human doses were reported for most 
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of the 2C-T drugs, and dose estimates started at 8 mg for the most potent compounds 
(Shulgin and Shulgin, 1995; Trachsel et al., 2013). A higher human dose (80-130 mg) was 
described for 2C-T-27 (Trachsel, 2012), consistent with the lower 5-HT2A receptor activation 
potency that was found in the present study. 
 
5. Conclusion 
We characterized sparsely studied potent psychoactive drugs, providing insights into 
the relationship between the structure and 5-HT2 receptor binding and activation of 
psychedelic phenethylamines. 2C-T drugs potently bound to 5-HT2A and 5-HT2C receptors 
and had affinity for 5-HT1A and α2A receptors. Furthermore, 2C-T drugs were potent 5-HT2A 
and 5-HT2B partial agonists with the exception of benzylthiophenethylamines, which had no 
or negligible activation potential for the 5-HT2B receptor. 
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Figure 
 
Fig. 1. Structures of 4-thio-substituted phenethylamines (2C-T drugs). 
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Tables 
Table 1. Serotonin receptor binding affinities and activation potencies. 
  5-HT1A  5-HT2A  5-HT2B  5-HT2C  Selectivity (binding ratios) 
 Receptor binding  Receptor binding Activation potency Activation efficacy  Activation potency Activation efficacy  Receptor binding  5-HT2A/5-
HT1A 
5-HT2A/5-
HT2C 
  Ki ± SD [nM]  Ki ± SD [nM] EC50 ± SD [nM] max ± SD [%]  EC50 ± SD [nM] max ± SD [%]  Ki ± SD [nM]    
2C-T-1 1,035 ± 125  49 ± 21 2.0 ± 0.1 75 ± 3  57 ± 38 58 ± 11  347 ± 129  21 7.1 
2C-T-3 812 ± 161  11 ± 5 7.7 ± 1.6 44 ± 6  44 ± 8 28 ± 7  40 ± 6  74 3.6 
2C-T-4 916 ± 86  54 ± 21 5.5 ± 0.7 56 ± 5  63 ± 11 75 ± 10  295 ± 28  17 5.5 
2C-T-7 878 ± 97  5.3 ± 0.6 1.2 ± 0.4 49 ± 12  52 ± 10 46 ± 12  54 ± 25  166 10 
2C-T-16 660 ± 74  9.2 ± 3.6 1.3 ± 0.6 57 ± 9  47 ± 32 36 ± 1  67 ± 15  72 7.3 
2C-T-19 1,019 ± 129  6.9 ± 3.3 12 ± 2 55 ± 6  369 ± 188 40 ± 3  101 ± 25  148 15 
2C-T-
21.5 
1,321 ± 193  14 ± 3 4.6 ± 1.4 66 ± 7  182 ± 12 40 ± 4  159 ± 77  94 11 
2C-T-22 1,915 ± 53  16 ± 1 15 ± 5 36 ± 2  110 ± 55 35 ± 15  151 ± 45  120 9.4 
2C-T-25 1,036 ± 134  21 ± 7 12 ± 2 49 ± 7  108 ± 35 32 ± 11  80 ± 32  49 3.8 
2C-T-27 1,166 ± 147  1.6 ± 0.5 26 ± 2 27 ± 4  >10,000   52 ± 12  729 33 
2C-T-28 1,904 ± 42  17 ± 6 5.7 ± 0.3 45 ± 7  81 ± 23 34 ± 16  135 ± 38  112 7.9 
2C-T-30 2,368 ± 22  9.5 ± 2.0 5.7 ± 2.4 40 ± 1  51 ± 34 61 ± 10  158 ± 45  249 17 
2C-T-31 1,063 ± 51  3.8 ± 1.1 53 ± 12 2.8 ± 0.7  3,309 ± 1,084 44 ± 13  157 ± 8  280 41 
2C-T-33 1,411 ± 38  1.7 ± 1.3 26 ± 8 40 ± 1  >10,000   75 ± 6  830 44 
              
2C-B 311 ± 46  6.9 ± 1.8 2.1 ± 0.8 92 ± 8  75 ± 14 52 ± 26  43 ± 4  45 6.2 
LSD 1.5 ± 0.4  5.3 ± 3.4 44 ± 14 73 ± 2  >10,000   14 ± 3  0.28 2.6 
Ki and EC50 values are given as nM (mean ± SD); activation efficacy (Emax) is given as percentage of maximum ± SD. 
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Table 2. Monoamine receptor and transporter binding affinities. 
 human TAAR1 rat TAAR1 mouse TAAR1 α1A α2A D2 NET DAT SERT 
 EC50 [nM] Ki [nM] Ki [nM] Ki [nM] Ki [nM] Ki [nM] Ki [nM] Ki [nM] Ki [nM] 
2C-T-1 >30,000 52 ± 8 1,877 ± 661 >6,510 334 ± 43 >4,400 >9,710 >8,710 >8,580 
2C-T-3 >30,000 8.0 ± 1.3 465 ± 236 >6,510 97 ± 12 >4,400 >9,710 >8,710 7,221 ± 470 
2C-T-4 >30,000 19 ± 5 2,337 ± 911 >6,510 217 ± 36 >4,400 >9,710 >8,710 >8,580 
2C-T-7 >30,000 10 ± 0 311 ± 61 >6,510 335 ± 49 >4,400 >9,710 >8,710 >8,580 
2C-T-16 >30,000 17 ± 7 453 ± 133 >6,510 229 ± 17 >4,400 >9,710 >8,710 >8,580 
2C-T-19 >30,000 4.8 ± 1.5 96 ± 33 >6,510 458 ± 45 >4,400 >9,710 >8,710 >8,580 
2C-T-21.5 >30,000 68 ± 11 1,674 ± 185 >6,510 383 ± 26 >4,400 >9,720 >8,710 >7,510 
2C-T-22 >30,000 38 ± 15 974 ± 17 >6,510 592 ± 39 >4,400 >9,720 >8,710 >7,510 
2C-T-25 >30,000 11 ± 1 359 ± 95 >6,510 279 ± 6 >6,270 >9,720 >8,710 >7,510 
2C-T-27 >30,000 10 ± 2 596 ± 197 >6,510 351 ± 43 >6,270 >9,720 4,760 ± 569 >7,510 
2C-T-28 >30,000 62 ± 19 426 ± 116 2,730 ± 653 331 ± 31 >6,270 >9,720 >8,710 >7,510 
2C-T-30 >30,000 29 ± 3 182 ± 52 2,297 ± 134 408 ± 42 >6,270 >9,720 >8,710 >7,510 
2C-T-31 >30,000 5.2 ± 0.6 55 ± 9 2,534 ± 88 804 ± 126 >6,270 >9,720 5,474 ± 54 >7,510 
2C-T-33 >30,000 38 ± 0 761 ± 117 3,628 ± 308 343 ± 72 >6,270 >9,720 7,706 ± 249 >7,510 
          
d-Methamphetamine 3,707 ± 587 257 ± 15 889 ± 49       
Ki and EC50 values are given as nM (mean ± SD). 
